1. AB0954 A randomised, double-blind trial comparing the efficacy, safety and immunogenicity of msb11022, a proposed biosimilar of adalimumab, versus adalimumab originator in patients with moderate-to-severe plaque psoriasis. (12th June 2018) Authors: Hercogová, J.; Papp, K.A.; Edwards, C.J.; Chyrok, V.; Halady, T.; Ullmann, M.; Vlachos, P. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 1602 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗